CustomNext-Cancer gives the flexibility to choose from up to 81 genes to accurately diagnose, treat, and manage patient’s cancer risks. All selected genes (excluding EPCAM and GREM1) are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for the following genes, if selected: PTEN (c.-1300 to c.-745), MLH1 (c.-337 to c.-194), and MSH2 (c.-318 to c.-65). For POLD1 and POLE, missense variants located outside of the exonuclease domains (codons 311-541 and 269-485, respectively) are not routinely reported. Testing to be consider if patient's complex personal and/or family history requires a unique panel of genes to assess (not found in an existing panel). CustomNext-Cancer can detect >99.9% of described mutations in the included genes, when present.
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1), BLM (BLM RecQ Like Helicase)
See More ...
Next-Generation Sequencing (NGS)